IN THE SPOTLIGHT

Exon 20: What You Need to Know About this Rare Form of Lung Cancer

Exon 20: What You Need to Know About this Rare Form of Lung Cancer

Osimertinib and Platinum Chemo Produces Unprecedented Results in NSCLC

Osimertinib and Platinum Chemo Produces Unprecedented Results in NSCLC

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study

Yale Cancer Center Expert Reports Significant Improvement in Survival for Lung Cancer Patients in the ADAURA Phase III Trial, involving AstraZeneca’s Targeted Therapy Drug, Tagrisso

Yale Cancer Center Expert Reports Significant Improvement in Survival for Lung Cancer Patients in the ADAURA Phase III Trial, involving AstraZeneca’s Targeted Therapy Drug, Tagrisso

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital

EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population

EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population

Targeted Drug Tagrisso Could Be Advance Against Lung Cancer

Targeted Drug Tagrisso Could Be Advance Against Lung Cancer

Adjuvant Osimertinib Shows Long-Term DFS Benefit in Resected EGFR-Mutated NSCLC

Adjuvant Osimertinib Shows Long-Term DFS Benefit in Resected EGFR-Mutated NSCLC

Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment

Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment